MDB Capital Holdings, LLC Class A common
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $21.8M
- Price
- $2.09
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.83%
- Volume
- 6.6K
About
MDB Capital Holdings, LLC functions primarily as a broker-dealer through its subsidiary operations. The company's activities are divided into two main areas: Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service division provides comprehensive broker-dealer services, focusing on arranging private and public securities offerings, and furnishing research for investment banking due diligence. Meanwhile, the Technology Development division is engaged in the advancement of synthetic biology technology. MDB Capital Holdings, LLC was established in 1997 and is based in Addison, Texas.
Quick stats
Shares outstanding10.4M
Computed float4.9M
Float / shares46.6%
Cash runway (months)9.3
Key info
SectorFinancial Services
IndustryFinancial - Capital Markets
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001934642
Websitehttps://www.mdb.com
AI Summary
AI-generated1/17
minorbullishpartnership
BioNTX and PatentVest Announce Multi-Year Strategic Partnership
Bio North Texas (BioNTX) and PatentVest announced a multi-year strategic partnership that embeds structured intellectual property diligence and commercialization-focused assessments into BioNTX's nationally recognized Rising Stars program for emerging life science companies.
PatentVest will contribute AI-enabled IP strategy, portfolio evaluations, and year-round founder support across BioNTX programming, including the iC³ Life Science & Healthcare Innovation Summit, under a collaboration the CEOs describe as running over the next three years.
No financial terms were disclosed. For the filer, the deal is primarily a pipeline and visibility win that positions the IP-services franchise in front of early-stage life science founders rather than a near-term revenue event.
Red flags
- Partnership announced with no financial terms, deal value, or revenue commitments disclosed
- Filer's ticker (MDBH) is not referenced anywhere in the release; linkage to the filer runs through the PatentVest business line only